Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)
about
MicroRNAs in Drug-induced Liver InjuryDrug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment OptionsSelected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohortRisk factors for idiosyncratic drug-induced liver injury.Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacologyRecent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Drug-induced liver injury: insights from genetic studies.Pharmacogenetics of drug-induced liver injury.Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity.Genetic association studies in drug-induced liver injury.The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.Drug-induced liver injury: the role of drug metabolism and transport.Antibiotic induced liver injury: what about children?Idiosyncratic drug-induced liver injury: an update on the 2007 overview.Drug metabolism and liver disease: a drug-gene-environment interaction.Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.Moxifloxacin induced fatal hepatotoxicity in a 72-year-old man: a case report.Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury.Death due to liver failure during endocrine therapy for premenopausal breast cancer.Drug-induced liver injury: is it somehow foreseeable?Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury.Idiosyncratic drug hepatotoxicity: a 2008 update.
P2860
Q26781801-8073B465-64CF-4088-8454-78C08201CD1CQ26781892-1ACD8D60-7206-4FDF-AB23-E6108BCE916FQ28537826-D2A91562-EE72-4831-A550-62BDDA6EB84CQ35168108-5FFD14B9-656F-477A-B023-E640A25B0249Q35681250-2D268BDE-1EFC-4368-AAE5-6DCDC6F4363DQ37121662-AA5E9F17-969D-4B7B-9571-3B6EE70EEB66Q37598897-B1F8D4DE-ECD8-42D6-84AC-BA17ADC6ADD7Q37770487-B6689102-708F-4ECB-959E-C3A1DCF1EB14Q37862739-CD82596B-7697-4A0D-A9E6-24F6EE26935AQ37931275-4611CBEA-050E-4CDB-895B-32CE91D9243FQ37979858-FC439B37-420A-478A-BA61-900D39346B8CQ38084215-33B40CB1-035C-435C-9D2B-395A7F41111EQ38144140-C5CC0964-50F6-4A10-A244-082E601F5EB3Q38145274-8E15A679-AFAA-4DF2-954D-34B75FBB23C7Q39037269-A5E87F43-C928-49B3-84B3-3798305DE99EQ42324494-FE917FA0-3B3A-46E7-BB63-AB852437DA6AQ42549700-1DB8A97D-1468-453D-9ED5-C33B9AB9CC98Q43005717-FB2FEEDE-4702-407B-9094-0C9FBFD6298CQ43060235-BBE95E4F-0061-4CAA-A582-CDCCE7C5EC21Q43109156-C3CE35DF-4AE3-4C36-B5CB-F75FDACA2A16Q50490710-292ED01C-D682-4E03-88AA-530DA63F3F84Q51712894-F3DDB664-A97A-414F-8F88-2B944B0CDEDA
P2860
Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI)
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Genetic polymorphisms of CYP2C ...... osyncratic liver injury (DILI)
@ast
Genetic polymorphisms of CYP2C ...... osyncratic liver injury (DILI)
@en
type
label
Genetic polymorphisms of CYP2C ...... osyncratic liver injury (DILI)
@ast
Genetic polymorphisms of CYP2C ...... osyncratic liver injury (DILI)
@en
prefLabel
Genetic polymorphisms of CYP2C ...... osyncratic liver injury (DILI)
@ast
Genetic polymorphisms of CYP2C ...... osyncratic liver injury (DILI)
@en
P2093
P2860
P356
P1476
Genetic polymorphisms of CYP2C ...... osyncratic liver injury (DILI)
@en
P2093
F Ruiz-Cabello
K Pachkoria
M I Lucena
M R Cabello
Spanish Group for the Study of ...... tías Asociadas a Medicamentos)
P2860
P304
P356
10.1038/SJ.BJP.0707122
P407
P577
2007-02-05T00:00:00Z